U.S. Department of Health & Human Services
More effective medications for pain are needed, but poorly predictive animal models, changes in biopharmaceutical industry focus, and perceived regulatory and reimbursement concerns have made research challenging. Through a suite of targeted research efforts, the Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative®, will accelerate the discovery and preclinical development of new medications and devices to treat pain.
Click Here to learn more about the 2020 NCATS ASPIRE Reduction-to-Practice Challenge
Research Programs
This program seeks to validate novel therapeutic targets using a variety of methods and model systems. These targets can be applied to future translational research to speed up the creation of effective non-addictive medications for pain and reduce reliance on opioids.
The Preclinical Screening Platform for Pain (PSPP) program will create a preclinical testing platform to identify and profile non-addictive therapeutics for pain. This platform will be instrumental in transitioning NIH HEAL Initiative preclinical research into clinical programs.
The NIH HEAL Initiative will support research to develop more accurate research models, use these models to identify potential new therapies, and accelerate studies of novel small molecule and biologic drug candidates for testing in humans.
The NIH HEAL Initiative will support preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain.
The NIH HEAL Initiative will advance device-based treatments for people who currently have no effective ways to manage their pain. Research will support target identification, late-stage translational therapeutic and diagnostic device development, verification and validation activities, and early clinical studies.
Through a robust multidisciplinary and trans-NIH project, the NIH HEAL Initiative will advance the discovery and rigorous validation of biomarkers for pain research and treatment. Successful development of biomarkers could help increase the use of biomarkers for patient selection in clinical trials. This could improve the efficacy of clinical trials and increase the chance that new therapeutics will advance to approval.
Funded Projects
Open Funding Opportunities
Closed Funding Opportunities
Collaboration Opportunities for Developing Drugs and Human Cell-Based Testing Platforms for Pain, Addiction and Overdose
Collaboration Opportunities for Developing Drugs and Human Cell-Based Testing Platforms for Pain, Addiction and Overdose
The NIH Helping to End Addiction Long-termSM Initiative, or NIH HEAL InitiativeSM, seeks to speed scientific solutions to the national opioid public health crisis.
Read more